Manas Makes Medicines

We are an AI-native biopharmaceutical company combining pioneering AI technology with the first principles of chemistry, physics, and biology to transform the clinical pipeline from target to medicine.

Our approach

Traditional drug development remains a critical bottleneck to human health. We are engineering a new standard of discovery: one defined by unprecedented speed, cost-efficiency, and molecular precision.

Neuro-symbolic AI

Frontier models built on first principles. We codify deep scientific domain rules from chemistry, physics, and biology.

End-to-end pipeline

From target identification to clinical trials, we leverage AI to accelerate every step of bringing life-saving medicines to patients.

Multiple modalities

A modality-versatile platform engineered to accelerate discovery across small molecules, antibodies, and siRNA therapies alike.

Global ecosystem

A global partnership infrastructure that redefines clinical efficiency — cutting timelines dramatically without compromising patient safety.

Humans in the loop

By combining human expertise with high-speed AI, our platform develops only the most viable and safe therapeutic leads.

Biologically informed

Reducing biological complexity through informed target ID and validation.

“Manas AI enables next-generation multi-modal therapeutics by transforming the pace and precision of drug discovery. For siRNA medicines, this translates into rapid innovation in delivery ligands and nucleic acid chemistry unlocking new levels of specificity, efficacy, and safety.”

“Manas AI’s atomic level frontier models represent a powerful, differentiated approach to tackling AI for drug discovery.”

“Manas is well positioned to uncover subtle structural and mechanistic relationships that were previously undetected with traditional methods, and to drive greater R&D productivity by reducing cycle times, lowering overall costs, and reducing error rates across the drug discovery enterprise.”

Craig Mello, Ph.D.

Nobel Laureate; Co-Founder, Althea Therapeutics

Peter Kim, Ph.D.

Stanford Professor; Former President, Merck Research Laboratories

Ken Frazier

Chairman, Health Assurance Initiatives, General Catalyst; Former Chairman and CEO, Merck

Latest updates

Manas AI Secures Strategic Advantage through Unique Deep Integration with Schrödinger’s Physics + AI Discovery Platform

Jan 12, 2026

Manas AI Announces $26M Seed Extension and the Appointment of Ujjwal Singh as Co-Founder and Chief Technology Officer

Sep 23, 2025

Manas AI Appoints Jonathan Baell, PhD, as Chief Scientific Officer

Apr 15, 2025